Tags

Type your tag names separated by a space and hit enter

Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome.
Br Med J 1978; 1(6110):402-4BM

Abstract

The clinical distribution of an antibody to a metabolite of practolol was investigated, particularly in relation to the oculomucocutaneous syndrome. Serum samples were obtained from patients with and without a history of adverse reaction to practolol and two groups of control patients who had never taken the drug. Five patients also participated in a challenge study. The presence of the antibody was found to be related to practolol administration, and antibody activity could be increased by antigenic challenge. The role of this antibody in the pathogenesis of the oculomucocutaneous syndrome remains uncertain. The lesions may be the result of a hitherto unknown type of hypersensitivity response to practolol.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

146533

Citation

Amos, H E., et al. "Possible Role of Antibody Specific for a Practolol Metabolite in the Pathogenesis of Oculomucocutaneous Syndrome." British Medical Journal, vol. 1, no. 6110, 1978, pp. 402-4.
Amos HE, Lake BG, Artis J. Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome. Br Med J. 1978;1(6110):402-4.
Amos, H. E., Lake, B. G., & Artis, J. (1978). Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome. British Medical Journal, 1(6110), pp. 402-4.
Amos HE, Lake BG, Artis J. Possible Role of Antibody Specific for a Practolol Metabolite in the Pathogenesis of Oculomucocutaneous Syndrome. Br Med J. 1978 Feb 18;1(6110):402-4. PubMed PMID: 146533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome. AU - Amos,H E, AU - Lake,B G, AU - Artis,J, PY - 1978/2/18/pubmed PY - 1978/2/18/medline PY - 1978/2/18/entrez SP - 402 EP - 4 JF - British medical journal JO - Br Med J VL - 1 IS - 6110 N2 - The clinical distribution of an antibody to a metabolite of practolol was investigated, particularly in relation to the oculomucocutaneous syndrome. Serum samples were obtained from patients with and without a history of adverse reaction to practolol and two groups of control patients who had never taken the drug. Five patients also participated in a challenge study. The presence of the antibody was found to be related to practolol administration, and antibody activity could be increased by antigenic challenge. The role of this antibody in the pathogenesis of the oculomucocutaneous syndrome remains uncertain. The lesions may be the result of a hitherto unknown type of hypersensitivity response to practolol. SN - 0007-1447 UR - https://www.unboundmedicine.com/medline/citation/146533/Possible_role_of_antibody_specific_for_a_practolol_metabolite_in_the_pathogenesis_of_oculomucocutaneous_syndrome_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/146533/ DB - PRIME DP - Unbound Medicine ER -